QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NYSE:AMRX

Amneal Pharmaceuticals (AMRX) Stock Forecast, Price & News

$4.18
-0.01 (-0.24%)
(As of 09/25/2023 ET)
Compare
Today's Range
$4.02
▼
$4.25
50-Day Range
$3.03
▼
$4.60
52-Week Range
$1.24
▼
$4.74
Volume
1.24 million shs
Average Volume
1.07 million shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.60
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Amneal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
10.0% Upside
$4.60 Price Target
Short Interest
Healthy
3.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
0.53mentions of Amneal Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$121,017 Sold Last Quarter
Proj. Earnings Growth
11.11%
From $0.45 to $0.50 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

769th out of 961 stocks

Pharmaceutical Preparations Industry

357th out of 452 stocks

See Top Rated MarketRank™ Stocks Here

AMRX stock logo

About Amneal Pharmaceuticals (NYSE:AMRX) Stock

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Price History

AMRX Stock News Headlines

September 24, 2023 | seekingalpha.com
Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
September 20, 2023 | americanbankingnews.com
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages
September 25, 2023 | Legacy Research (Ad)
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
September 11, 2023 | finance.yahoo.com
Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) institutional investors lost 11% over the past week but have profited from longer-term gains
September 7, 2023 | msn.com
Truist Securities Reiterates Amneal Pharmaceuticals Inc - (AMRX) Buy Recommendation
September 7, 2023 | msn.com
Amneal gets approval for generic injectable on FDA's shortage list
September 6, 2023 | markets.businessinsider.com
Amneal Gets FDA Approval For Calcium Gluconate Injection
September 6, 2023 | markets.businessinsider.com
Analyst Ratings for Amneal Pharmaceuticals
September 25, 2023 | Behind the Markets (Ad)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
September 6, 2023 | finance.yahoo.com
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
September 6, 2023 | markets.businessinsider.com
Amneal Pharma Says FDA Approves Lisdexamfetamine Dimesylate Capsules
September 6, 2023 | finance.yahoo.com
Amneal Receives First Product Approval in China
September 6, 2023 | finance.yahoo.com
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
August 31, 2023 | msn.com
Amneal Pharmaceuticals Inc - (AMRX) Price Target Increased by 50.00% to 5.36
August 29, 2023 | finance.yahoo.com
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
August 24, 2023 | finance.yahoo.com
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
August 16, 2023 | benzinga.com
Massive Insider Trade At Amneal Pharmaceuticals
August 8, 2023 | msn.com
Truist Securities Maintains Amneal Pharmaceuticals Inc - (AMRX) Buy Recommendation
August 7, 2023 | msn.com
Barclays Maintains Amneal Pharmaceuticals Inc - (AMRX) Overweight Recommendation
August 7, 2023 | finance.yahoo.com
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q2 2023 Earnings Call Transcript
August 6, 2023 | markets.businessinsider.com
Goldman Sachs Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)
August 5, 2023 | finance.yahoo.com
Q2 2023 Amneal Pharmaceuticals Inc Earnings Call
August 4, 2023 | seekingalpha.com
Amneal Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation
August 4, 2023 | markets.businessinsider.com
Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength
August 4, 2023 | finance.yahoo.com
Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say
August 4, 2023 | finance.yahoo.com
Amneal Reports Second Quarter 2023 Financial Results
July 27, 2023 | finance.yahoo.com
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMRX Company Calendar

Last Earnings
8/04/2023
Today
9/25/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AMRX
CUSIP
N/A
CIK
1723128
Web
www.amneal.com
Phone
(908) 947-3120
Fax
908-947-3146
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.60
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+12.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
9.07
P/E Growth
N/A
Net Income
$-129,990,000.00
Net Margins
-0.09%
Pretax Margin
0.64%
Return on Equity
101.26%
Return on Assets
4.48%

Debt

Debt-to-Equity Ratio
17.18
Current Ratio
1.83
Quick Ratio
1.12

Sales & Book Value

Annual Sales
$2.21 billion
Price / Sales
0.56
Cash Flow
$1.38 per share
Price / Cash Flow
2.95
Book Value
$0.61 per share
Price / Book
6.69

Miscellaneous

Outstanding Shares
306,310,000
Free Float
224,282,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.31
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Chirag K. PatelMr. Chirag K. Patel (Age 56)
    Co-Founder, Co-CEO, Pres & Director
    Comp: $1.44M
  • Mr. Chintu Patel R.Ph (Age 51)
    R.Ph., Co-Founder, Co-CEO & Director
    Comp: $1.46M
  • Mr. Anastasios G. Konidaris (Age 56)
    Exec. VP & CFO
    Comp: $856.38k
  • Mr. Jason B. Daly Esq. (Age 49)
    Sr. VP, Chief Legal Officer & Corp. Sec.
    Comp: $782.53k
  • Ms. Nikita ShahMs. Nikita Shah (Age 44)
    Exec. VP & Chief HR Officer
    Comp: $757.4k
  • Mr. Andrew S. Boyer (Age 57)
    Exec. VP & Chief Commercial Officer of Generics
    Comp: $1.06M
  • Mr. Anthony DiMeo
    Sr. Director of Investor Relations
  • Mr. Gregory Sgammato
    Sr. VP of Corp. Devel.
  • Mr. Pranav Mehta
    Sr. VP of Strategic Sourcing & Supply Management
  • Dr. Nikunj Patel
    Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AMRX Stock - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued twelve-month target prices for Amneal Pharmaceuticals' shares. Their AMRX share price forecasts range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.60 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of the year. Since then, AMRX shares have increased by 105.0% and is now trading at $4.08.
View the best growth stocks for 2023 here.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our AMRX earnings forecast.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced its quarterly earnings data on Friday, August, 4th. The company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The firm earned $599.05 million during the quarter, compared to analysts' expectations of $562.49 million. Amneal Pharmaceuticals had a negative net margin of 0.09% and a positive trailing twelve-month return on equity of 101.26%.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals updated its FY 2023 earnings guidance on Friday, August, 4th. The company provided earnings per share guidance of $0.45-$0.55 for the period, compared to the consensus estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.62%), Rubric Capital Management LP (0.85%), State Street Corp (0.73%), Geode Capital Management LLC (0.72%), LSV Asset Management (0.42%) and Charles Schwab Investment Management Inc. (0.41%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.08.

How much money does Amneal Pharmaceuticals make?

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $1.25 billion and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.02) on an earnings per share basis.

How many employees does Amneal Pharmaceuticals have?

The company employs 7,600 workers across the globe.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.

This page (NYSE:AMRX) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -